SYNLAB AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.5 EUR | 0.00% |
|
-0.38% | -8.06% |
| Apr. 22 | Synlab Faces Cyber Attack in Italy | MT |
| Apr. 21 | Dpa-AFX Overview: COMPANIES - The most important news from the weekend | DP |
| Sales 2024 * | 2.91B 3.12B | Sales 2025 * | 3.1B 3.32B | Capitalization | 2.31B 2.47B |
|---|---|---|---|---|---|
| Net income 2024 * | 91M 97.3M | Net income 2025 * | 69M 73.78M | EV / Sales 2024 * | 1.33 x |
| Net Debt 2024 * | 1.57B 1.68B | Net Debt 2025 * | 1.61B 1.72B | EV / Sales 2025 * | 1.26 x |
| P/E ratio 2024 * |
25.6
x | P/E ratio 2025 * |
33.9
x | Employees | 23,538 |
| Yield 2024 * |
0.86% | Yield 2025 * |
2.1% | Free-Float | 14.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on SYNLAB AG
More press releases
| 1 week | -0.38% | ||
| Current month | -4.11% | ||
| 1 month | -0.57% | ||
| 3 months | -11.09% | ||
| 6 months | +5.58% | ||
| Current year | -8.06% |
1 week
10.42
10.64
1 month
10.1011.16
Current year
10.1012.43
1 year
8.0212.43
3 years
6.6825.00
5 years
6.6825.00
10 years
6.6825.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mathieu Floreani
CEO | Chief Executive Officer | 56 | 21-01-25 |
Sami Badarani
DFI | Director of Finance/CFO | 61 | 21-01-25 |
Henrik Andreasen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ebsworth
CHM | Chairman | 69 | 21-01-10 |
| Founder | 63 | 97-12-31 | |
Peter Catterall
BRD | Director/Board Member | 55 | 21-01-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.29% | 125 M€ | -.--% | ||
| 0.55% | 17 M€ | -.--% | - | |
| 0.18% | 18 M€ | +7.68% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 10.5 | 0.00% | 32,734 |
| 24-04-25 | 10.5 | -0.38% | 12,457 |
| 24-04-24 | 10.54 | +0.19% | 2,576 |
| 24-04-23 | 10.52 | -0.38% | 5,804 |
| 24-04-22 | 10.56 | +0.19% | 8,188 |
Delayed Quote Xetra, April 26, 2024 at 11:35 am EDT
More quotes
Synlab AG is a Germany based clinical laboratory and medical diagnostic services provider. The Company is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
10.5
EUR
Average target price
14.5
EUR
Spread / Average Target
+38.10%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.06% | 2.46B | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- SYAB Stock
